Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Muparfostat (PI-88) is a mixture of highly sulfated mannose oligosaccharides derived from yeast. It acts as a heparanase inhibitor and heparan sulfate mimetic with antiangiogenic and antimetastatic properties. Muparfostat inhibits the enzyme heparanase and binds to angiogenic growth factors such as Vascular endothelial growth factor (VEGF) and Fibroblast growth factor 1 (FGF-1)/Fibroblast growth factor 2 (FGF-2) to block their activity in tumor angiogenesis and metastasis[1][2][5]. Dacarbazine is an alkylating agent used primarily for malignant melanoma and Hodgkin's disease; it works by interfering with DNA replication in cancer cells[6]. The combination has been investigated for advanced melanoma due to potential synergistic effects on tumor growth inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on muparfostat + dacarbazine.